During treatment, cancer cells with deficient HR DNA repair are found to exhibit striking sensitivities to PARP inhibition, and the activity of PARPi in patients with BRCA mutant cancers is clearly observed [2,3,11,12]. Here, PARP1 is linked to cancer.